Skip to main content

Table 5 Adverse events

From: Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis

Adverse events

CNI, n = 86

CTX, n = 86

RTX, n = 86

Nausea/diarrhea

1

3

0

Allergies/rashes

1

0

2

hypertrichosis

2

0

0

Impaired glucose tolerance

1

2

1

Diabetes

3

3

1

Osteoporosis

0

0

2

Leukopenia

1

1

7**

Elevated liver enzymes

3

1

6

Pneumonia

1

3

3

Other infection

2

6

1

Cancer

3

2

0

Cardio-cerebrovascular events

3

1

0

Death

2

3

0

  1. Data are shown as n. **p < 0.01